<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:mayoclinic="http://mayoclinic.org"
>

<channel>
	<title>Research - Mayo Clinic News Network</title>
	<atom:link href="https://newsnetwork.mayoclinic.org/category/research/feed/" rel="self" type="application/rss+xml" />
	<link>https://newsnetwork.mayoclinic.org/category/research/</link>
	<description>News Resources</description>
	<lastBuildDate>Thu, 12 Feb 2026 16:41:10 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.1</generator>
	<item>
		<title>Lung cancer drug offers a surprising new treatment against ovarian cancer</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/lung-cancer-drug-offers-a-surprising-new-treatment-against-ovarian-cancer/</link>
		
		<dc:creator><![CDATA[rebeccabromelkamp]]></dc:creator>
		<pubDate>Thu, 12 Feb 2026 16:41:08 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Minnesota]]></category>
		<category><![CDATA[News Releases]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Arun Kanakkanthara]]></category>
		<category><![CDATA[Dr. John Weroha]]></category>
		<category><![CDATA[Minnesota News Releases]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=410485</guid>

					<description><![CDATA[<p>ROCHESTER, Minn. — A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better. PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/lung-cancer-drug-offers-a-surprising-new-treatment-against-ovarian-cancer/">Lung cancer drug offers a surprising new treatment against ovarian cancer</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="682" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/Woman-hugs-her-mother_GettyImages-1165575988-1024x682.jpg" alt="A woman hugs her mother as they both smile. The mother is wearing a headscarf indicating cancer treatment." class="wp-image-410497" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/Woman-hugs-her-mother_GettyImages-1165575988-1024x682.jpg 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/Woman-hugs-her-mother_GettyImages-1165575988-300x200.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/Woman-hugs-her-mother_GettyImages-1165575988-768x512.jpg 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/Woman-hugs-her-mother_GettyImages-1165575988-1536x1024.jpg 1536w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/Woman-hugs-her-mother_GettyImages-1165575988.jpg 1688w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Getty</figcaption></figure>



<p>ROCHESTER, Minn. — A new <a href="https://www.science.org/doi/10.1126/scitranslmed.adt8706" target="_blank" rel="noreferrer noopener">study</a> published by <a href="https://www.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> researchers suggests that <a href="https://www.mayoclinic.org/diseases-conditions/ovarian-cancer/symptoms-causes/syc-20375941" target="_blank" rel="noreferrer noopener">ovarian cancer</a> cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better.</p>



<p>PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair. However, many tumors eventually stop responding, even when the drugs initially show results. The new research identifies a way cancer cells may survive PARP inhibitor treatment early on, and it points to a potential strategy to block that response.</p>



<p>In the study, researchers found that ovarian cancer cells rapidly activate a pro-survival program after exposure to PARP inhibitors. A key driver of this response is FRA1, a transcription factor that helps turn on genes that allow cancer cells to adapt and avoid cell death.</p>



<p>"This work shows that drug resistance does not always emerge slowly over time — cancer cells can activate survival programs very early after treatment begins," says <a href="https://www.mayo.edu/research/faculty/kanakkanthara-arun-ph-d/bio-20445738" target="_blank" rel="noreferrer noopener">Arun Kanakkanthara, Ph.D.</a>, an oncology investigator at Mayo Clinic and a senior author of the study. "By targeting that early response, we may be able to improve how well existing therapies work and potentially delay or prevent resistance."</p>



<p>The research team tested whether brigatinib, an FDA-approved drug currently used to treat certain lung cancers, could block this survival response and enhance the effects of PARP inhibitors. Brigatinib was selected because of its ability to inhibit multiple signaling pathways involved in cancer cell survival.</p>



<p>The results showed that combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Importantly, this effect was seen only in cancer cells, not in normal cells, suggesting the potential for a more targeted and safer treatment approach.</p>



<p>Surprisingly, the researchers discovered that brigatinib helps in a completely new way. Rather than acting through traditional DNA repair pathways, brigatinib shuts down two key signaling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on to survive. Blocking both signals at once weakened the cancer cells' ability to adapt and resist treatment, leaving them far more vulnerable to PARP inhibitors.</p>



<p>The researchers also found a potential clue for identifying which patients might benefit most from this treatment. Tumors with higher levels of the signaling molecules FAK and EPHA2 responded better to the drug combination. Other data suggest that ovarian cancers with high levels of these molecules are often more aggressive, highlighting the promise of this approach for harder-to-treat cases.</p>



<p>"From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer," says <a href="https://www.mayoclinic.org/biographies/weroha-john-j-m-d-ph-d/bio-20055686" target="_blank" rel="noreferrer noopener">John Weroha, M.D., Ph.D.</a>, a medical oncologist at Mayo Clinic and a senior author of the study. "By combining mechanistic insights from Dr. Kanakkanthara's laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes."</p>



<p>This research sheds new light on how ovarian cancer evades treatment, and it points to a promising strategy for improving patient outcomes.</p>



<p>###</p>



<p><strong>About Mayo Clinic</strong> <br><a href="https://www.mayoclinic.org/about-mayo-clinic" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the&nbsp;<a href="https://newsnetwork.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic News Network</a>&nbsp;for additional Mayo Clinic news.</p>



<p><strong>Media contact:</strong></p>



<ul class="wp-block-list">
<li>Julie Ferris-Tillman, Ph.D., Mayo Clinic Communications, <a href="mailto:newsbureau@mayo.edu">newsbureau@mayo.edu</a><a id="_msocom_1"></a></li>
</ul>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/lung-cancer-drug-offers-a-surprising-new-treatment-against-ovarian-cancer/">Lung cancer drug offers a surprising new treatment against ovarian cancer</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/Woman-hugs-her-mother_GettyImages-1165575988_1x1.jpg</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/Woman-hugs-her-mother_GettyImages-1165575988_16x9.jpg</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Arun Kanakkanthara]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. John Weroha]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Minnesota News Releases]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[News Releases]]></mayoclinic:mctag>	</item>
		<item>
		<title>Tomorrow&amp;#8217;s Cure:  Mayo Clinic Proceedings</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/tomorrows-cure-mayo-clinic-proceedings/</link>
		
		<dc:creator><![CDATA[jftmayo]]></dc:creator>
		<pubDate>Wed, 11 Feb 2026 13:11:11 +0000</pubDate>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Medical Innovation]]></category>
		<category><![CDATA[Podcast]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Karl Nath]]></category>
		<category><![CDATA[Dr. Vincent Rajkumar]]></category>
		<category><![CDATA[Tomorrow's Cure]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=410222</guid>

					<description><![CDATA[<p>This&amp;#160;episode&amp;#160;of "Tomorrow's Cure"&amp;#160;explores the importance of shepherding discovery through one of the most prominent journals in the field,&amp;#160;Mayo Clinic&amp;#160;Proceedings. Listen as&amp;#160;Dr.&amp;#160;Vincent Rajkumar,&amp;#160;a&amp;#160;Mayo Clinic hematologist and oncologist&amp;#160;and an associate editor for the journal,&amp;#160;and&amp;#160;Dr. Karl Nath,&amp;#160;a&amp;#160;Mayo Clinic nephrologist&amp;#160;and&amp;#160;current editor,&amp;#160;as they talk about the journal's 100 years of history and its future.&amp;#160;&amp;#160; Prior to its early format as [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/tomorrows-cure-mayo-clinic-proceedings/">Tomorrow&amp;#8217;s Cure:  Mayo Clinic Proceedings</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large"><img decoding="async" width="1024" height="576" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/TC_Proceedings_YT-Thumbnail_1280x720-1024x576.png" alt="Graphic, Mayo Clinic Proceedings: Stories that Changed Care , Season 4, episode 4" class="wp-image-410225" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/TC_Proceedings_YT-Thumbnail_1280x720-1024x576.png 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/TC_Proceedings_YT-Thumbnail_1280x720-300x169.png 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/TC_Proceedings_YT-Thumbnail_1280x720-768x432.png 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/TC_Proceedings_YT-Thumbnail_1280x720.png 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



<p>This&amp;nbsp;episode&amp;nbsp;of "<a href="https://www.youtube.com/watch?v=0DmAM6qqZyg&amp;amp;list=PLSWR1ylG_6JZd7nHPPgpIaoq_iRHgXRoF">Tomorrow's Cure</a>"&amp;nbsp;explores the importance of shepherding discovery through one of the most prominent journals in the field,&amp;nbsp;<a href="https://www.mayoclinicproceedings.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic&amp;nbsp;Proceedings</a>. Listen as&amp;nbsp;<a href="https://www.mayo.edu/research/faculty/rajkumar-s-vincent-m-d/bio-00085953" target="_blank" rel="noreferrer noopener">Dr.&amp;nbsp;Vincent Rajkumar</a>,&amp;nbsp;a&amp;nbsp;Mayo Clinic hematologist and oncologist&amp;nbsp;and an associate editor for the journal,&amp;nbsp;and&amp;nbsp;<a href="https://www.mayo.edu/research/faculty/nath-karl-a-m-b-ch-b-m-d/bio-00027413" target="_blank" rel="noreferrer noopener">Dr. Karl Nath</a>,&amp;nbsp;a&amp;nbsp;Mayo Clinic nephrologist&amp;nbsp;and&amp;nbsp;current editor,&amp;nbsp;as they talk about the journal's 100 years of history and its future.&amp;nbsp;&amp;nbsp;</p>



<p>Prior to its early format as an internal newsletter, the Mayo brothers&amp;nbsp;hired&amp;nbsp;<a href="https://history.mayoclinic.org/books-films/heritage-films/maud-mellish-wilson-a-singular-voice/" target="_blank" rel="noreferrer noopener">Maud Mellish Wilson</a>&amp;nbsp;to serve as librarian&amp;nbsp;and organizer of editorial materials in&amp;nbsp;1907.&amp;nbsp;Around 1919, she began taking notes at a recurring weekly meeting to discuss discoveries.&amp;nbsp;That meeting grew with the&amp;nbsp;clinic,&amp;nbsp;and consultants began to travel to other places to learn and discuss medicine.&amp;nbsp;As faculty grew, the inability to gather them all in one meeting&amp;nbsp;sparked&amp;nbsp;the development of the Bulletin of the Mayo Foundation,&amp;nbsp;which&amp;nbsp;evolved into a full-fledged journal in 1926.&amp;nbsp;&amp;nbsp;</p>



<p>The editors talk with host&amp;nbsp;<a href="https://www.mprnews.org/people/cathy-wurzer" target="_blank" rel="noreferrer noopener">Cathy Wurzer</a>&amp;nbsp;about the value of peer-reviewed research and experts in a field gathering to encourage and debate scientific progress.&amp;nbsp;"We&amp;nbsp;have to&amp;nbsp;take ourselves with a lot of caution and seriousness because once&amp;nbsp;it's&amp;nbsp;published in the&amp;nbsp;Mayo Clinic Proceedings&amp;nbsp;with the Mayo brand, it carries a certain level of trust," says&amp;nbsp;Dr.&amp;nbsp;Rajkumar.&amp;nbsp;&amp;nbsp;</p>



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="fluidEmbed"><iframe id="videoid0DmAM6qqZyg"  title="Mayo Clinic Proceedings: Stories that Changed the World | Tomorrow&amp;#039;s Cure Season 4 Episode 4" width="500" height="281" src="https://www.youtube.com/embed/0DmAM6qqZyg?feature=oembed&amp;enablejsapi=1" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></div>
</div></figure>



<p>The podcast also explores what future iterations of scientific journals could look like and how they&amp;nbsp;engage&amp;nbsp;social media, including a new Fellowship in Training Editors program the group could introduce as early as this year. Advances in AI, digital&amp;nbsp;health&amp;nbsp;and more will continue to change the mechanics of journals. Mayo Clinic Proceedings is already using&amp;nbsp;<a href="https://www.youtube.com/@MayoProceedings" target="_blank" rel="noreferrer noopener">YouTube</a>&amp;nbsp;to its advantage.&amp;nbsp;"(Social media)&amp;nbsp;is&amp;nbsp;a roadmap for communication for humanity in whatever form or setting," says Dr.&amp;nbsp;Nath.&amp;nbsp;&amp;nbsp;</p>



<p>In this conversation, the editors also talk about the breakthrough research first published in Mayo Clinic Proceedings from using viruses to treat cancer to&amp;nbsp;a platelet-derived exosome product that affects tissues and promotes healing. These wide-reaching discoveries and more were first&amp;nbsp;published&amp;nbsp;in the journal&amp;nbsp;and continue to influence their fields.&amp;nbsp;&amp;nbsp;</p>



<p>Listen to the latest episode of "<a href="https://careinfo.mayoclinic.org/tomorrows-cure-podcast" target="_blank" rel="noreferrer noopener">Tomorrow's Cure</a>"&nbsp;wherever you get your podcasts. You can explore the full library of episodes and guests on the&nbsp;show's&nbsp;<a href="https://www.youtube.com/playlist?list=PLSWR1ylG_6JZd7nHPPgpIaoq_iRHgXRoF" target="_blank" rel="noreferrer noopener">page</a>.&nbsp;&nbsp;&nbsp;</p>



<p></p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/tomorrows-cure-mayo-clinic-proceedings/">Tomorrow&amp;#8217;s Cure:  Mayo Clinic Proceedings</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/TC_Proceedings_Episode-Art_3000x3000.png</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/02/TC_Proceedings_YT-Thumbnail_1280x720.png</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Karl Nath]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Vincent Rajkumar]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Tomorrow's Cure]]></mayoclinic:mctag>	</item>
		<item>
		<title>Advancing&nbsp;epilepsy&nbsp;care:&nbsp;Mayo Clinic neurologist&nbsp;Dr. Gregory Worrell&nbsp;</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/advancing-epilepsy-care-mayo-clinic-neurologist-dr-gregory-worrell/</link>
		
		<dc:creator><![CDATA[Alison Satake]]></dc:creator>
		<pubDate>Fri, 30 Jan 2026 14:30:00 +0000</pubDate>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Neurosciences]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Gregory Worrell]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=409905</guid>

					<description><![CDATA[<p>Dr. Gregory Worrell&nbsp;shares&nbsp;how technological innovation is transforming the&nbsp;future of epilepsy&nbsp;care.&nbsp;</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/advancing-epilepsy-care-mayo-clinic-neurologist-dr-gregory-worrell/">Advancing&nbsp;epilepsy&nbsp;care:&nbsp;Mayo Clinic neurologist&nbsp;Dr. Gregory Worrell&nbsp;</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong>ROCHESTER, Minn.</strong>&amp;nbsp;—<strong>&amp;nbsp;</strong><a href="https://www.mayo.edu/research/faculty/worrell-gregory-a-m-d-ph-d/bio-00027235" target="_blank" rel="noreferrer noopener"><strong>Gregory Worrell, M.D., Ph.D.</strong></a>, is a&amp;nbsp;physician-scientist and&amp;nbsp;neurologist whose&amp;nbsp;research&amp;nbsp;focus is&amp;nbsp;<a href="https://www.mayoclinic.org/diseases-conditions/epilepsy/symptoms-causes/syc-20350093" target="_blank" rel="noreferrer noopener">epilepsy</a>&amp;nbsp;— a neurological disorder that causes seizures and affects more than&amp;nbsp;50 million people&amp;nbsp;worldwide. He is the William L. McKnight-3M Professor of Neuroscience at Mayo Clinic. Dr. Worrell&amp;nbsp;shares&amp;nbsp;how technological innovation is transforming the&amp;nbsp;future of epilepsy&amp;nbsp;care.&amp;nbsp;</p>



<p><strong><a href="https://youtu.be/vlN-PpDHfp8" target="_blank" rel="noreferrer noopener">Watch: Dr. Worrell discusses advancing epilepsy care</a></strong></p>



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="fluidEmbed"><iframe loading="lazy" id="videoidhttpsyoutubevlNPpDHfp8"  title="Gregory Worrell, M.D., Ph.D. - The goal of BIONIC" width="500" height="281" src="https://www.youtube.com/embed/vlN-PpDHfp8?feature=oembed&amp;enablejsapi=1" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></div>
</div></figure>



<p><strong>&amp;nbsp;Journalists: Broadcast-quality sound bites are available in the downloads at the end of the post. Please courtesy: "Mayo Clinic News Network." Name super/CG: Gregory Worrell, M.D., Ph.D./ Neurology /Mayo Clinic.</strong></p>



<p><br><strong>Why is epilepsy such a challenging condition to treat?</strong>&amp;nbsp;<br>Epilepsy affects people across the entire lifespan, from infancy through older adulthood. About one-third of patients continue to have seizures despite medication. Many also experience&amp;nbsp;disabling&amp;nbsp;comorbidities such as sleep disturbances, memory&amp;nbsp;problems&amp;nbsp;and mood disorders. Treating epilepsy effectively requires addressing all&amp;nbsp;of these challenges, not just seizures alone.&amp;nbsp;</p>



<p><strong>How does a team-based approach improve epilepsy care?</strong>&amp;nbsp;<br>Addressing epilepsy requires collaboration across many specialties, including&amp;nbsp;basic neuroscience, engineering,&amp;nbsp;neurology, neurosurgery,&amp;nbsp;neuroradiology&amp;nbsp;and psychiatry. By combining&amp;nbsp;expertise&amp;nbsp;and&amp;nbsp;leveraging&amp;nbsp;advances in biology, imaging,&amp;nbsp;engineering,&amp;nbsp;computing&amp;nbsp;and artificial intelligence, we can better meet the complex and unmet needs of patients.&amp;nbsp;&amp;nbsp;</p>



<p><strong>What is the&amp;nbsp;Bioelectronics Neuromodulation Innovation to Cure&amp;nbsp;(BIONIC)&amp;nbsp;Initiative, and why is it important for epilepsy care?</strong>&amp;nbsp;<br>The BIONIC&amp;nbsp;initiative is focused on changing the course of epilepsy therapy and diagnostics.&amp;nbsp;We're&amp;nbsp;in&amp;nbsp;a period of rapid technological acceleration — advances in artificial intelligence, neurotechnology, computing and connected devices. These tools allow us to deliver and adjust therapies in real time and to receive feedback from people with epilepsy as they go about their daily lives. This creates new opportunities to better understand epilepsy, create new&amp;nbsp;therapies&amp;nbsp;and improve patient care.&amp;nbsp;</p>



<p><strong>How do these technologies help people living with epilepsy day to day?</strong>&amp;nbsp;<br>Today, we can track seizures as well as common&amp;nbsp;epilepsy-related&amp;nbsp;comorbidities such as sleep problems, memory&amp;nbsp;issues&amp;nbsp;and mood disorders. Importantly, we can also intervene using neuromodulation&amp;nbsp;using&amp;nbsp;electrical&amp;nbsp;brain&amp;nbsp;stimulation,&amp;nbsp;to help suppress seizures and improve these comorbidities. This&amp;nbsp;technology&amp;nbsp;allows care to extend beyond the clinic and into a patient's home.&amp;nbsp;</p>



<p><strong>What kinds of devices are being developed through BIONIC?</strong>&amp;nbsp;<br>We're&amp;nbsp;developing&amp;nbsp;a&amp;nbsp;next-generation neuromodulation&amp;nbsp;platform with&amp;nbsp;devices that are fully implantable&amp;nbsp;and integrated with wearables and computing. These devices include electrodes placed in the brain and have sensing capabilities that allow continuous recording of brain activity. The data can be securely transmitted through a handheld device to the cloud. The system enables analysis that can guide therapy&amp;nbsp;and&amp;nbsp;drive&amp;nbsp;better&amp;nbsp;understanding of&amp;nbsp;seizures and related conditions.&amp;nbsp;</p>



<p><strong>What can clinicians and researchers learn from this brain data?</strong>&amp;nbsp;<br>By continuously recording brain activity, we can track seizures, sleep patterns,&amp;nbsp;memory&amp;nbsp;and mood. This data allows us to adjust electrical therapies in a more personalized way.&amp;nbsp;Ultimately, our&amp;nbsp;goal is to forecast seizures before they happen and deliver adaptive therapies that&amp;nbsp;prevent&amp;nbsp;seizures&amp;nbsp;before they occur&amp;nbsp;and address the broader impact of epilepsy on daily life.&amp;nbsp;</p>



<p><strong>How do these new devices compare to earlier generations?</strong>&amp;nbsp;<br>Earlier devices were groundbreaking for their time, but they had fewer capabilities. The devices&amp;nbsp;we're&amp;nbsp;preparing for clinical trials are significantly smaller, more powerful,&amp;nbsp;rechargeable&amp;nbsp;and offer expanded&amp;nbsp;stimulation,&amp;nbsp;sensing&amp;nbsp;and streaming capabilities. This&amp;nbsp;represents&amp;nbsp;a major step forward in both technology and patient experience.&amp;nbsp;</p>



<p><strong>What is the long-term vision of the BIONIC Initiative?</strong>&amp;nbsp;<br>Our vision is to build more effective therapies, prevent seizures before they&amp;nbsp;occur&amp;nbsp;and directly target comorbidities. With current&amp;nbsp;newly developed&amp;nbsp;technologies, these goals are now achievable, and BIONIC is focused on translating them into real-world patient benefits.&amp;nbsp;</p>



<p><strong>Why is collaboration beyond Mayo Clinic essential?</strong>&amp;nbsp;<br>These challenges&amp;nbsp;can't&amp;nbsp;be solved by one person or one institution alone. Collaboration with other academic centers, industry&amp;nbsp;partners&amp;nbsp;and most importantly,&amp;nbsp;patients is essential. A technology that&amp;nbsp;doesn't&amp;nbsp;have a clear path to commercialization, even if&amp;nbsp;it's&amp;nbsp;innovative, will&amp;nbsp;likely&amp;nbsp;only&amp;nbsp;help a&amp;nbsp;relatively&amp;nbsp;small&amp;nbsp;number of people.&amp;nbsp;</p>



<p><strong>How do patients factor into the development of these therapies?</strong>&amp;nbsp;<br>Partnering with patients is critical. We need to understand what matters most to them&amp;nbsp;and&amp;nbsp;what they need to improve their quality of life. Their input helps guide technology development&amp;nbsp;so that it truly addresses real-world needs.&amp;nbsp;</p>



<p><strong>What is the&amp;nbsp;ultimate goal&amp;nbsp;of BIONIC?</strong>&amp;nbsp;<br>The goal of BIONIC is to bring&amp;nbsp;all of&amp;nbsp;these elements together into a unified effort to create the future of epilepsy therapy — one that is more personalized,&amp;nbsp;proactive&amp;nbsp;and focused on the whole patient.&amp;nbsp;It is important to realize that&amp;nbsp;the neuromodulation&amp;nbsp;technologies developed for epilepsy will have&amp;nbsp;a&amp;nbsp;wide impact on many other diseases of the brain and mind.&amp;nbsp;<br>&amp;nbsp;<br><strong>###&amp;nbsp;</strong>&amp;nbsp;</p>



<p><strong>About Mayo&amp;nbsp;Clinic&amp;nbsp;</strong>&amp;nbsp;<br><a href="https://www.mayoclinic.org/about-mayo-clinic" target="_blank" rel="noreferrer noopener">Mayo Clinic</a>&amp;nbsp;is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion,&amp;nbsp;expertise&amp;nbsp;and answers to everyone who needs healing. Visit the&amp;nbsp;<a href="https://newsnetwork.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic News Network</a>&amp;nbsp;for&amp;nbsp;additional&amp;nbsp;Mayo Clinic news.&amp;nbsp;&amp;nbsp;</p>



<p><strong>Media contact:</strong>&amp;nbsp;</p>



<ul class="wp-block-list">
<li>Tia Ford, Mayo Clinic Communications,&amp;nbsp;<a href="mailto:newsbureau@mayo.edu" target="_blank" rel="noreferrer noopener">newsbureau@mayo.edu</a>&amp;nbsp;&amp;nbsp;<br>&amp;nbsp;<br>&amp;nbsp;</li>
</ul>



<p></p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/advancing-epilepsy-care-mayo-clinic-neurologist-dr-gregory-worrell/">Advancing&nbsp;epilepsy&nbsp;care:&nbsp;Mayo Clinic neurologist&nbsp;Dr. Gregory Worrell&nbsp;</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/GregoryWorrell1x1.jpg</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/GregoryWorrell16x9.jpg</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Gregory Worrell]]></mayoclinic:mctag>	</item>
		<item>
		<title>Mayo Clinic uses gene editing to reverse inherited kidney disease in preclinical study</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-uses-gene-editing-to-reverse-inherited-kidney-disease-in-preclinical-study/</link>
		
		<dc:creator><![CDATA[mbroadfoot]]></dc:creator>
		<pubDate>Thu, 29 Jan 2026 13:45:23 +0000</pubDate>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Minnesota]]></category>
		<category><![CDATA[News Releases]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Xiaogang Li]]></category>
		<category><![CDATA[Minnesota News Releases]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=409935</guid>

					<description><![CDATA[<p>ROCHESTER, Minn. — Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible for autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disorder. A single treatment of the gene therapy slowed kidney cyst growth, improved heart and liver health, and extended survival in preclinical models of [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-uses-gene-editing-to-reverse-inherited-kidney-disease-in-preclinical-study/">Mayo Clinic uses gene editing to reverse inherited kidney disease in preclinical study</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Researchers-and-laboratory-technicians-work-in-a-busy-laboratory_WF4324336_0165-1024x576.jpg" alt="Researchers and laboratory technicians work in a laboratory" class="wp-image-409985" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Researchers-and-laboratory-technicians-work-in-a-busy-laboratory_WF4324336_0165-1024x576.jpg 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Researchers-and-laboratory-technicians-work-in-a-busy-laboratory_WF4324336_0165-300x169.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Researchers-and-laboratory-technicians-work-in-a-busy-laboratory_WF4324336_0165-768x432.jpg 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Researchers-and-laboratory-technicians-work-in-a-busy-laboratory_WF4324336_0165-1536x864.jpg 1536w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Researchers-and-laboratory-technicians-work-in-a-busy-laboratory_WF4324336_0165.jpg 2000w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></figure>



<p>ROCHESTER, Minn. — <a href="https://www.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible for autosomal dominant <a href="https://newsnetwork.mayoclinic.org/discussion/science-saturday-confronting-polycystic-kidney-disease-a-silent-killer/?cjdata=MXxOfDB8WXww&amp;amp;cjevent=0a8219cbe9d911f082600abd0a82b821&amp;amp;cm_mmc=CJ-_-100357191-_-5250933-_-Evergreen+Link+for+Mayo+Clinic+Diet&amp;amp;utm_source=cj&amp;amp;utm_content=100357191&amp;amp;utm_capaign=3-months" target="_blank" rel="noreferrer noopener">polycystic kidney disease</a> (ADPKD), the most common inherited kidney disorder.</p>



<p>A single treatment of the gene therapy slowed kidney cyst growth, improved heart and liver health, and extended survival in preclinical models of ADPKD. The findings were <a href="https://www.nature.com/articles/s41467-025-65997-1" target="_blank" rel="noreferrer noopener">published</a> in Nature Communications.</p>


<div class="wp-block-image">
<figure class="alignright size-medium"><img loading="lazy" decoding="async" width="262" height="300" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Xiaogang-Li-262x300.jpg" alt="Portrait of Dr. Xiaogang Li" class="wp-image-409980" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Xiaogang-Li-262x300.jpg 262w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Xiaogang-Li.jpg 682w" sizes="auto, (max-width: 262px) 100vw, 262px" /><figcaption class="wp-element-caption">Xiaogang Li, Ph.D.</figcaption></figure>
</div>


<p>"This is the first time we've been able to show that base editing can effectively and safely correct a disease-causing mutation in the kidney in a complex biological system," says <a href="https://www.mayo.edu/research/faculty/li-xiaogang-ph-d/bio-20453268" target="_blank" rel="noreferrer noopener">Xiaogang Li, Ph.D.</a>, nephrology researcher and senior author of the study. "Instead of managing symptoms, this strategy goes after the underlying cause of the disease."</p>



<p><a href="https://www.mayoclinic.org/diseases-conditions/polycystic-kidney-disease/symptoms-causes/syc-20352820?cjdata=MXxOfDB8WXww&amp;amp;cjevent=71874690e9d911f082ee0b1f0a82b836&amp;amp;cm_mmc=CJ-_-100357191-_-5250933-_-Evergreen+Link+for+Mayo+Clinic+Diet&amp;amp;utm_source=cj&amp;amp;utm_content=100357191&amp;amp;utm_capaign=3-months" target="_blank" rel="noreferrer noopener">ADPKD</a> affects an estimated 12 million people worldwide. The disease is caused primarily by mutations in the PKD1 or PKD2 genes and leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure. Many patients also develop complications outside the kidneys, including heart enlargement and liver disease.</p>



<p>Current treatments can slow disease progression but do not address its genetic root. The new approach, developed by Mayo Clinic investigators, uses a form of <a href="https://newsnetwork.mayoclinic.org/discussion/science-saturday-the-gene-editing-tool-crispr-explained/?cjdata=MXxOfDB8WXww&amp;amp;cjevent=b0050e8de9d811f082600abd0a82b821&amp;amp;cm_mmc=CJ-_-100357191-_-5250933-_-Evergreen+Link+for+Mayo+Clinic+Diet&amp;amp;utm_source=cj&amp;amp;utm_content=100357191&amp;amp;utm_capaign=3-months" target="_blank" rel="noreferrer noopener">CRISPR-based gene editing</a> known as base editing to precisely correct a single-letter DNA mutation in the PKD1 gene.</p>



<p>In the study, researchers engineered two versions of a base editor: one designed to work broadly across multiple organs and another tailored specifically to kidney cells. Delivered using adeno-associated virus (AAV) vectors, a single dose of the therapy corrected the PKD1 mutation in a significant proportion of cells in kidney tissue and, depending on the editor used, in the heart and liver as well.</p>


<div class="wp-block-image">
<figure class="alignleft size-medium"><img loading="lazy" decoding="async" width="300" height="250" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/4250422-001-0-72ppi-300x250.jpg" alt="Illustration of a healthy kidney and a polycystic kidney" class="wp-image-409981" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/4250422-001-0-72ppi-300x250.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/4250422-001-0-72ppi.jpg 632w" sizes="auto, (max-width: 300px) 100vw, 300px" /></figure>
</div>


<p>Preclinical models treated early in life had significantly reduced kidney cyst growth, better kidney function, less heart enlargement, improved liver health and longer survival. Importantly, the researchers found no evidence of harmful off-target genetic changes or significant immune reactions.</p>



<p>"Our results suggest this could one day be a treatment that meaningfully changes the course of disease," Dr. Li says. "That is fundamentally different from lifelong therapies that only slow progression."</p>



<p>The kidney has historically been difficult to target with gene-editing therapies. This study provides the first in vivo evidence that base editing can work efficiently in kidney tissue, opening the door to similar approaches for other inherited kidney diseases.</p>



<p>The research team also demonstrated that kidney-specific gene editing can limit genetic changes to the intended organ, a strategy that may enhance safety as therapies move closer to human testing.</p>



<p>"Being able to precisely control where editing happens is critical," Dr. Li says. "It allows us to maximize benefit while minimizing risk."<strong></strong></p>



<p>The work advances Mayo Clinic's Genesis initiative, which aims to prevent organ failure and restore function through regenerative medicine, precision genomics and advanced therapies.&amp;nbsp;</p>



<p>Ongoing studies are focused on refining base-editing tools to address a broader range of PKD mutations, evaluating whether treatment can be effective after cysts have already formed, and developing alternative delivery methods — including nonviral options such as nanoparticles — to support future clinical use.</p>



<p>"If these approaches translate successfully to humans, they could reduce or even eliminate the need for chronic medication, delay kidney failure and significantly improve quality of life for patients with ADPKD," Dr. Li says.</p>



<p>For a complete list of authors, disclosures and funding, review the&amp;nbsp;<a href="https://www.nature.com/articles/s41467-025-65997-1" target="_blank" rel="noreferrer noopener">study</a>.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;</p>



<p>###&amp;nbsp;&amp;nbsp;</p>



<p><strong>About Mayo Clinic</strong> <br><a href="https://www.mayoclinic.org/about-mayo-clinic" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the <a href="https://newsnetwork.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic News Network</a> for additional Mayo Clinic news.</p>



<p><strong>Media contact:</strong></p>



<ul class="wp-block-list">
<li>Kelley Luckstein, Mayo Clinic Communications, <a href="mailto:newsbureau@mayo.edu" target="_blank" rel="noreferrer noopener">newsbureau@mayo.edu</a></li>
</ul>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-uses-gene-editing-to-reverse-inherited-kidney-disease-in-preclinical-study/">Mayo Clinic uses gene editing to reverse inherited kidney disease in preclinical study</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Researchers-and-laboratory-technicians-work-in-a-busy-laboratory_WF4324336_0165_1x1.jpg</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Researchers-and-laboratory-technicians-work-in-a-busy-laboratory_WF4324336_0165.jpg</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Xiaogang Li]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Minnesota News Releases]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[News Releases]]></mayoclinic:mctag>	</item>
		<item>
		<title>Rewriting the future of rheumatoid arthritis: How early detection is transforming prevention&nbsp;</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/rewriting-the-future-of-rheumatoid-arthritis-how-early-detection-is-transforming-prevention/</link>
		
		<dc:creator><![CDATA[jftmayo]]></dc:creator>
		<pubDate>Wed, 28 Jan 2026 17:05:33 +0000</pubDate>
				<category><![CDATA[AI and Digital Health]]></category>
		<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Medical Innovation]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Rheumatoid Arthritis]]></category>
		<category><![CDATA[Tomorrow's Cure]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=409916</guid>

					<description><![CDATA[<p>This episode of&nbsp;the&nbsp;"Tomorrow's&nbsp;Cure"&nbsp;podcast&nbsp;discusses developments in rheumatoid arthritis research and the emerging technologies shaping&nbsp;what's&nbsp;possible in care. Featuring&nbsp;Dr. John Davis, III, Mayo Clinic rheumatologist and Dr. Kevin Deane, University of Colorado rheumatologist, the episode highlights how early‑stage research and emerging technologies are reshaping&nbsp;what's&nbsp;possible in rheumatoid arthritis care.&nbsp; Rheumatoid arthritis&nbsp;is an autoimmune condition that affects far more than [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/rewriting-the-future-of-rheumatoid-arthritis-how-early-detection-is-transforming-prevention/">Rewriting the future of rheumatoid arthritis: How early detection is transforming prevention&nbsp;</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Rheumatology_YT-Thumbnail_1280x720-1024x576.png" alt="Graphic for Tomorrow's Cure episode 2 Predictive Medicine: Rethinking Rheumatoid Arthritis" class="wp-image-409920" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Rheumatology_YT-Thumbnail_1280x720-1024x576.png 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Rheumatology_YT-Thumbnail_1280x720-300x169.png 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Rheumatology_YT-Thumbnail_1280x720-768x432.png 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Rheumatology_YT-Thumbnail_1280x720.png 1280w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></figure>



<p>This episode of&nbsp;the&nbsp;"<a href="https://www.youtube.com/watch?v=mPeC3QIslqI" target="_blank" rel="noreferrer noopener">Tomorrow's&nbsp;Cure</a>"&nbsp;podcast&nbsp;discusses developments in <a href="https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a> research and the emerging technologies shaping&nbsp;what's&nbsp;possible in care. Featuring&nbsp;<a href="https://www.mayo.edu/research/faculty/davis-john-m-iii-m-d/bio-00027697" target="_blank" rel="noreferrer noopener">Dr. John Davis, III</a>, Mayo Clinic rheumatologist and Dr. Kevin Deane, University of Colorado rheumatologist, the episode highlights how early‑stage research and emerging technologies are reshaping&nbsp;what's&nbsp;possible in rheumatoid arthritis care.&nbsp;</p>



<p>Rheumatoid arthritis&nbsp;is an autoimmune condition that affects far more than joints. Crucially, researchers now know that autoantibodies,&nbsp;such as anti-cyclic citrullinated peptide (anti‑CCP)&nbsp;and <a href="https://www.mayoclinic.org/tests-procedures/rheumatoid-factor/about/pac-20384800" target="_blank" rel="noreferrer noopener">rheumatoid factor</a>,&nbsp;often develop years before diagnosis, signaling early immune system disruption.&nbsp;</p>



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="fluidEmbed"><iframe loading="lazy" id="videoidmPeC3QIslqI"  title="Predictive Medicine: Rethinking Rheumatoid Arthritis | Tomorrow&amp;#039;s Cure Season 4 Episode 2" width="500" height="281" src="https://www.youtube.com/embed/mPeC3QIslqI?feature=oembed&amp;enablejsapi=1" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></div>
</div></figure>



<p>Traditional blood tests&amp;nbsp;predict&amp;nbsp;future&amp;nbsp;rheumatoid arthritis&amp;nbsp;only&amp;nbsp;about 30% of the time&amp;nbsp;—&amp;nbsp;too uncertain for preventive treatment. To close this gap, researchers&amp;nbsp;turn&amp;nbsp;to AI and&amp;nbsp;multisource&amp;nbsp;data&amp;nbsp;such as genetic information, lifestyle and environmental exposures, microbiome patterns, imaging and clinical records,&amp;nbsp;and wearable health metrics.&amp;nbsp;AI can piece together complex risk profiles that traditional methods&amp;nbsp;can't, helping&amp;nbsp;identify&amp;nbsp;individuals most likely to develop the disease and when.&amp;nbsp;</p>



<p>New evidence suggests&amp;nbsp;rheumatoid arthritis&amp;nbsp;may start at mucosal surfaces&amp;nbsp;such&amp;nbsp;as the lungs,&amp;nbsp;gut&amp;nbsp;or gums&amp;nbsp;before affecting joints. Environmental factors&amp;nbsp;such as&amp;nbsp;smoke,&amp;nbsp;pollution&amp;nbsp;and airborne particles may play a role in triggering early immune activation.&amp;nbsp;</p>



<p>At the same time, the gut microbiome is&amp;nbsp;emerging&amp;nbsp;as a powerful predictor of both&amp;nbsp;rheumatoid arthritis&amp;nbsp;risk and treatment response. Certain bacteria influence inflammation and can even&amp;nbsp;metabolize medications such as methotrexate, affecting how well patients respond.&amp;nbsp;</p>



<p>Over the next decade, experts&amp;nbsp;anticipate&amp;nbsp;transformative shifts in rheumatology,&amp;nbsp;including more precise biomarkers and antibody panels;&amp;nbsp;AI-guided prediction tools that can lead to personalized, data-driven treatment plans;&amp;nbsp;expanded virtual care options to increase access;&amp;nbsp;and a deeper understanding of environmental and immune triggers.&amp;nbsp;&amp;nbsp;</p>



<p>"I think this is where we need to go&amp;nbsp;… trying to put together a lot of data that we can digitize about an individual,&amp;nbsp;such as&amp;nbsp;health, risk factors, behaviors, even wearable data,&amp;nbsp;and analyze it&amp;nbsp;using AI to identify people who could be at risk long before symptoms appear,"&amp;nbsp;Dr.&amp;nbsp;Davis&amp;nbsp;says. The long‑term goal is clear:&amp;nbsp;identify&amp;nbsp;rheumatoid arthritis&amp;nbsp;before joint damage occurs&amp;nbsp;and&amp;nbsp;ultimately prevent&amp;nbsp;the disease altogether.&amp;nbsp;</p>



<p>Listen to the latest episode of&nbsp;"<a href="https://careinfo.mayoclinic.org/tomorrows-cure-podcast?mc_id=global&amp;amp;utm_source=newsnetwork&amp;amp;utm_medium=l&amp;amp;utm_content=tcseasonthreeepisodeone&amp;amp;utm_campaign=mayoclinic&amp;amp;geo=global&amp;amp;placementsite=enterprise&amp;amp;invsrc=other&amp;amp;cauid=193335" target="_blank" rel="noreferrer noopener">Tomorrow's Cure</a>"&nbsp;wherever you get your podcasts. You can explore the full library of episodes and guests on the&nbsp;show's&nbsp;<a href="https://www.youtube.com/playlist?list=PLSWR1ylG_6JZd7nHPPgpIaoq_iRHgXRoF" target="_blank" rel="noreferrer noopener">page</a>.&nbsp;</p>



<p></p>



<p></p>



<p><br></p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/rewriting-the-future-of-rheumatoid-arthritis-how-early-detection-is-transforming-prevention/">Rewriting the future of rheumatoid arthritis: How early detection is transforming prevention&nbsp;</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Rheumatology_Episode-Art_3000x3000.png</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Rheumatology_YT-Thumbnail_1280x720.png</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Rheumatoid Arthritis]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Tomorrow's Cure]]></mayoclinic:mctag>	</item>
		<item>
		<title>Global study identifies gap between expectations, experience in perimenopause</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/global-study-identifies-gap-between-expectations-experience-in-perimenopause/</link>
		
		<dc:creator><![CDATA[rebeccabromelkamp]]></dc:creator>
		<pubDate>Wed, 28 Jan 2026 14:01:00 +0000</pubDate>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Florida]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Mary Hedges]]></category>
		<category><![CDATA[Florida News Releases]]></category>
		<category><![CDATA[News Releases]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=409941</guid>

					<description><![CDATA[<p>JACKSONVILLE, Fla. — A new international study — believed to be the largest of its kind — examined what people know about perimenopause and what symptoms they experience. The results reveal a clear gap between what perimenopause symptoms people expect and what they experience. Mayo Clinic researchers published a collaborative research study with Flo, a [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/global-study-identifies-gap-between-expectations-experience-in-perimenopause/">Global study identifies gap between expectations, experience in perimenopause</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Women-look-at-cellphone-in-cafe_GettyImages-1456857560-1024x683.jpg" alt="Women look at cellphone in cafe" class="wp-image-409947" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Women-look-at-cellphone-in-cafe_GettyImages-1456857560-1024x683.jpg 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Women-look-at-cellphone-in-cafe_GettyImages-1456857560-300x200.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Women-look-at-cellphone-in-cafe_GettyImages-1456857560-768x512.jpg 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Women-look-at-cellphone-in-cafe_GettyImages-1456857560-1536x1024.jpg 1536w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Women-look-at-cellphone-in-cafe_GettyImages-1456857560.jpg 1687w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></figure>



<p>JACKSONVILLE, Fla. — A new international study — believed to be the largest of its kind — examined what people know about perimenopause and what symptoms they experience. The results reveal a clear gap between what perimenopause symptoms people expect and what they experience.</p>



<p><a href="https://www.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> researchers published a collaborative research <a href="https://journals.lww.com/menopausejournal/fulltext/9900/global_perspectives_on_perimenopause__a_digital.602.aspx" target="_blank" rel="noreferrer noopener">study</a> with Flo, a women's health application, to assess the <a href="https://www.mayoclinic.org/diseases-conditions/perimenopause/symptoms-causes/syc-20354666" target="_blank" rel="noreferrer noopener">perimenopause</a> symptoms of 17,494 people from 158 countries. The study results are published in <a href="https://menopause.org/professional-resources/menopause-journal-nm" target="_blank" rel="noreferrer noopener">Menopause</a>, the official journal of The Menopause Society.</p>



<p>Perimenopause marks the time leading up to the final menstrual period and includes the year after it ends. This transition can begin as early as the 30s and last for several years. Although it affects health and daily life, researchers have studied it far less than <a href="https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397" target="_blank" rel="noreferrer noopener">menopause</a>.</p>



<p>"This study shines a light on how little we still understand about perimenopause and how much it affects people's daily lives," says first author <a href="https://www.mayoclinic.org/biographies/hedges-mary-s-m-d/bio-20055284" target="_blank" rel="noreferrer noopener">Mary Hedges, M.D.</a>, a community internal medicine physician at <a href="https://www.mayoclinic.org/patient-visitor-guide/florida" target="_blank" rel="noreferrer noopener">Mayo Clinic in Florida</a>. "At Mayo Clinic, we're working to expand that understanding so we can improve awareness and guide care that truly meets the needs of each patient."</p>



<p>Among more than 12,000 participants over age 35, the most common reported symptoms were fatigue (83%), exhaustion (83%), irritability (80%), low mood (77%), sleep problems (76%), digestive issues (76%) and anxiety (75%).</p>



<p>When asked what they associate with perimenopause, participants most often named hot flashes (71%), sleep problems (68%) and weight gain (65%). However, for those who said they were in perimenopause, 95% reported exhaustion and 93% reported <a href="https://www.mayoclinic.org/symptoms/fatigue/basics/causes/sym-20050894" target="_blank" rel="noreferrer noopener">fatigue</a> — far higher than the rate of hot flashes. Exhaustion is a general decrease in performance, impaired memory, decreased concentration, and forgetfulness, whereas fatigue is physical exhaustion.</p>



<p>These findings show that fatigue, mood changes and sleep-related issues are central to many people's perimenopause experiences, the study authors say. Hormone changes may affect the body's natural rhythms and restorative sleep, while mood changes can be influenced by hormones, inflammation and diet.</p>



<p>The research highlights that perimenopause symptoms can significantly affect daily life, relationships and work. Responsibilities such as caregiving and coexisting health conditions may add to the strain, increasing fatigue and emotional stress.</p>



<p>Mayo Clinic researchers say the study underscores the importance of rethinking how clinicians approach midlife health. They emphasize that understanding what people are truly experiencing — not just what is traditionally expected — is essential to improving care and communication during this life stage.</p>



<p>Mayo Clinic continues to study how biological, lifestyle and social factors influence perimenopause symptoms and how greater awareness can help improve patient care. This work supports Mayo Clinic's vision to transform the practice of medicine through research that addresses real-world needs and leads to more informed, compassionate care.</p>



<p>###</p>



<p><strong>About Mayo Clinic</strong><br><a href="https://www.mayoclinic.org/about-mayo-clinic" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the <a href="https://newsnetwork.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic News Network</a> for additional Mayo Clinic news.</p>



<p><strong>Media contact:</strong></p>



<ul class="wp-block-list">
<li>Julie Ferris-Tillman, Ph.D., Mayo Clinic Communications, <a href="mailto:newsbureau@mayo.edu">newsbureau@mayo.edu</a></li>
</ul>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/global-study-identifies-gap-between-expectations-experience-in-perimenopause/">Global study identifies gap between expectations, experience in perimenopause</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Women-look-at-cellphone-in-cafe_GettyImages-1456857560_1x1.jpg</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Women-look-at-cellphone-in-cafe_GettyImages-1456857560_16x9.jpg</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Mary Hedges]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Florida News Releases]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[News Releases]]></mayoclinic:mctag>	</item>
		<item>
		<title>New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/new-study-links-combination-of-hormone-therapy-and-tirzepatide-to-greater-weight-loss-after-menopause/</link>
		
		<dc:creator><![CDATA[Jessica Saenz]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 23:31:00 +0000</pubDate>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Florida]]></category>
		<category><![CDATA[News Releases]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Maria Daniela Hurtado Andrade]]></category>
		<category><![CDATA[Dr. Regina Castaneda]]></category>
		<category><![CDATA[Florida News Releases]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=409761</guid>

					<description><![CDATA[<p>JACKSONVILLE, Fla. — A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, &amp;#38; Women's Health, could expand treatment possibilities for millions [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/new-study-links-combination-of-hormone-therapy-and-tirzepatide-to-greater-weight-loss-after-menopause/">New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="682" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Portrait-if-a-yarn-store-owner-standing-in-front-of-a-rack-of-yarn_GettyImages-2211563357-1024x682.jpg" alt="Portrait if a middle-aged woman yarn store owner standing in front of a rack of yarn" class="wp-image-409775" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Portrait-if-a-yarn-store-owner-standing-in-front-of-a-rack-of-yarn_GettyImages-2211563357-1024x682.jpg 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Portrait-if-a-yarn-store-owner-standing-in-front-of-a-rack-of-yarn_GettyImages-2211563357-300x200.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Portrait-if-a-yarn-store-owner-standing-in-front-of-a-rack-of-yarn_GettyImages-2211563357-768x511.jpg 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Portrait-if-a-yarn-store-owner-standing-in-front-of-a-rack-of-yarn_GettyImages-2211563357-1536x1022.jpg 1536w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Portrait-if-a-yarn-store-owner-standing-in-front-of-a-rack-of-yarn_GettyImages-2211563357.jpg 1690w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></figure>



<p>JACKSONVILLE, Fla. — A new study led by <a href="https://www.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking <a href="https://www.mayoclinic.org/drugs-supplements/tirzepatide-subcutaneous-route/description/drg-20534045" target="_blank" rel="noreferrer noopener">tirzepatide</a>, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanogw%2Farticle%2FPIIS3050-5038(25)00145-1%2Ffulltext&amp;amp;data=05%7C02%7CSaenz.Jessica%40mayo.edu%7Ce48ccd7048a14ce4fa7908de592723a7%7Ca25fff9c3f634fb29a8ad9bdd0321f9a%7C0%7C0%7C639046222303357075%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;amp;sdata=nXamtX8R0iOLgYrT2hxqtpCJUZHYHlrXz15w%2BxMpL7o%3D&amp;amp;reserved=0" target="_blank" rel="noreferrer noopener">The Lancet Obstetrics, Gynaecology, &amp;amp; Women's Health</a>, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.</p>


<div class="wp-block-image">
<figure class="alignright size-medium"><img loading="lazy" decoding="async" width="300" height="300" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Castaneda-300x300.jpg" alt="portrait of Dr. Regina Castaneda" class="wp-image-409769" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Castaneda-300x300.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Castaneda-150x150.jpg 150w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Castaneda.jpg 404w" sizes="auto, (max-width: 300px) 100vw, 300px" /><figcaption class="wp-element-caption">Regina Castaneda, M.D.</figcaption></figure>
</div>


<p><a href="https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397" target="_blank" rel="noreferrer noopener">Menopause</a> can accelerate age-related weight gain and increase the likelihood of developing overweight and obesity, which are major risk factors for cardiovascular disease, type 2 diabetes and other conditions. The decline in estrogen levels characteristic of menopause is also linked to changes independent of weight that can potentially raise <a href="https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-minute-menopause-and-the-heart-connection/" target="_blank" rel="noreferrer noopener">cardiovascular risk</a>. "This study provides important insights for developing more effective and personalized strategies for managing cardiometabolic risk in postmenopausal women," says Regina Castaneda, M.D., postdoctoral research fellow at Mayo Clinic and first author of the study.</p>



<p><a href="https://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-therapy/art-20046372" target="_blank" rel="noreferrer noopener">Hormone therapy</a> is the most effective first-line treatment for menopausal symptoms, including hot flashes and night sweats, which affect up to 75% of postmenopausal women. While evidence on how this therapy may interact with weight-loss medications is limited, some research has shown that postmenopausal women using hormone therapy experience greater weight loss when treated with the GLP-1-based obesity medication <a href="https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/description/drg-20406730" target="_blank" rel="noreferrer noopener">semaglutide</a>.</p>



<p>No previous studies have examined whether hormone therapy might influence outcomes with tirzepatide. Dr. Castaneda and a team of researchers set out to investigate this relationship by reviewing data from 120 participants with overweight or obesity who received tirzepatide for weight management for 12 or more months. Patients receiving tirzepatide along with hormone therapy were compared to participants with similar characteristics who were not using hormone therapy.</p>


<div class="wp-block-image">
<figure class="alignleft size-medium"><img loading="lazy" decoding="async" width="300" height="300" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Hurtado-300x300.jpg" alt="Portrait of Dr. Maria Daniela Hurtado Andrade" class="wp-image-409768" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Hurtado-300x300.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Hurtado-150x150.jpg 150w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Hurtado.jpg 486w" sizes="auto, (max-width: 300px) 100vw, 300px" /><figcaption class="wp-element-caption">Maria Daniela Hurtado Andrade, M.D., Ph.D.</figcaption></figure>
</div>


<p>"In this observational study, women who used menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone. Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss," says <a href="https://www.mayo.edu/research/faculty/hurtado-andrade-maria-daniela-m-d-ph-d/bio-20490372" target="_blank" rel="noreferrer noopener">Maria Daniela Hurtado Andrade, M.D., Ph.D.</a>, endocrinologist at Mayo Clinic and senior author of the study.</p>



<p>"It is possible that women using hormone therapy were already engaged in healthier behaviors, or that menopause symptom relief improved sleep and quality of life, making it easier to stay engaged with dietary and physical activity changes."</p>



<p>Dr. Castaneda says, while more studies that control for these factors are needed, the findings are clinically meaningful. "The magnitude of this difference warrants future studies that could help clarify how GLP-1-based obesity medications and menopausal hormone therapy may interact. Interestingly, preclinical data suggest a potential synergy, with estrogen appearing to enhance the appetite-suppressing effects of GLP-1," says Dr. Castaneda.</p>



<p>"Next, we plan to test these observations in a randomized clinical trial and determine if benefits extend beyond weight loss — specifically, whether hormone therapy also enhances the effects of these medications on cardiometabolic measures," adds Dr. Hurtado Andrade. "If confirmed, this work could speed the development and adoption of new, evidence-based strategies to reduce this risk for millions of postmenopausal women navigating this life stage."</p>



<p>This research was funded by the Mayo Clinic Center for Women's Health Research. Review the <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanogw%2Farticle%2FPIIS3050-5038(25)00145-1%2Ffulltext&amp;amp;data=05%7C02%7CSaenz.Jessica%40mayo.edu%7Ce48ccd7048a14ce4fa7908de592723a7%7Ca25fff9c3f634fb29a8ad9bdd0321f9a%7C0%7C0%7C639046222303357075%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;amp;sdata=nXamtX8R0iOLgYrT2hxqtpCJUZHYHlrXz15w%2BxMpL7o%3D&amp;amp;reserved=0" target="_blank" rel="noreferrer noopener">study</a> for a complete list of authors, disclosures and funding.</p>



<p>###</p>



<p><strong>About Mayo Clinic</strong> <br><a href="https://www.mayoclinic.org/about-mayo-clinic" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the <a href="https://newsnetwork.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic News Network</a> for additional Mayo Clinic news.</p>



<p><strong>Media contact:</strong></p>



<ul class="wp-block-list">
<li>Tia Ford, Mayo Clinic Communications, <a href="mailto:newsbureau@mayo.edu">newsbureau@mayo.edu</a></li>
</ul>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/new-study-links-combination-of-hormone-therapy-and-tirzepatide-to-greater-weight-loss-after-menopause/">New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Portrait-if-a-yarn-store-owner-standing-in-front-of-a-rack-of-yarn_GettyImages-2211563357_1x1.jpg</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Portrait-if-a-yarn-store-owner-standing-in-front-of-a-rack-of-yarn_GettyImages-2211563357_16x9.jpg</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Maria Daniela Hurtado Andrade]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Regina Castaneda]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Florida News Releases]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[News Releases]]></mayoclinic:mctag>	</item>
		<item>
		<title>Tomorrow&amp;#8217;s Cure: 3D bioprinting living human skin to improve wound care,&nbsp;testing&nbsp;</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/tomorrows-cure-3d-bioprinting-living-human-skin-to-improve-wound-care-testing/</link>
		
		<dc:creator><![CDATA[jftmayo]]></dc:creator>
		<pubDate>Wed, 21 Jan 2026 13:40:06 +0000</pubDate>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Podcast]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Saranya Wyles]]></category>
		<category><![CDATA[Tomorrow's Cure]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=409620</guid>

					<description><![CDATA[<p>On this week's launch of the fourth season of "Tomorrow's Cure," the first episode features two pioneers at the intersection of biology and technology. Together, they explore a fast-moving frontier in regenerative medicine: 3D bioprinting living, humanized skin models&amp;#160;built from real human cells and biologic building blocks. The podcast episode features&nbsp;Saranya Wyles, M.D., Ph.D.,&nbsp;a dermatologist [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/tomorrows-cure-3d-bioprinting-living-human-skin-to-improve-wound-care-testing/">Tomorrow&amp;#8217;s Cure: 3D bioprinting living human skin to improve wound care,&nbsp;testing&nbsp;</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="wp-block-image">
<figure class="aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Skinspan-Bioprinting_YT-Thumbnail_1280x720-1024x576.jpg" alt="Graphic for Tomorrow's Cure, episode 1 3D skin 16x9" class="wp-image-409653" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Skinspan-Bioprinting_YT-Thumbnail_1280x720-1024x576.jpg 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Skinspan-Bioprinting_YT-Thumbnail_1280x720-300x169.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Skinspan-Bioprinting_YT-Thumbnail_1280x720-768x432.jpg 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Skinspan-Bioprinting_YT-Thumbnail_1280x720.jpg 1280w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></figure>
</div>


<p>On this week's launch of the fourth season of "<a href="https://careinfo.mayoclinic.org/tomorrows-cure-podcast?mc_id=global&amp;amp;utm_source=newsnetwork&amp;amp;utm_medium=l&amp;amp;utm_content=tcseasontwoepisodeeight&amp;amp;utm_campaign=mayoclinic&amp;amp;geo=global&amp;amp;placementsite=enterprise&amp;amp;invsrc=other&amp;amp;cauid=190207">Tomorrow's Cure</a>," the first episode features two pioneers at the intersection of biology and technology. Together, they explore a fast-moving frontier in regenerative medicine: 3D bioprinting living, humanized skin model<strong>s</strong>&amp;nbsp;built from real human cells and biologic building blocks.</p>



<p>The podcast episode features&nbsp;<a href="https://www.mayoclinic.org/biographies/wyles-saranya-p-m-d-ph-d/bio-20518649">Saranya Wyles, M.D., Ph.D</a>.,&nbsp;a dermatologist at&nbsp;<a href="https://www.mayoclinic.org/about-mayo-clinic">Mayo Clinic</a>&nbsp;in Rochester, and&nbsp;<a href="https://www.cmu.edu/bme/People/Faculty/profile/afeinberg.html">Adam Feinberg, Ph.D.</a>, principal investigator of the Regenerative Biomaterials and Therapeutics Group at Carnegie Mellon University.</p>



<p>Dr. Wyles describes skin as a set of "cake layers," including the epidermis, dermis and hypodermis. She proposes that people think about skin span. "It's an idea derived from health span and life span. Our concept is that we can have optimally functioning skin at the level of structure but also at the level of its function, serving as a barrier preventing infection for longer," Dr. Wyles says. "The skin is a mirror to your systemic health."&amp;nbsp;</p>



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<div class="fluidEmbed"><iframe loading="lazy" id="videoidPsni7MsovIA"  title="3D Bioprinted Skin: Breakthroughs in Regenerative Medicine | Tomorrow&amp;#039;s Cure Season 4 Episode 1" width="500" height="281" src="https://www.youtube.com/embed/Psni7MsovIA?feature=oembed&amp;enablejsapi=1" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></div>
</div></figure>



<p>A major goal is to model how skin changes over time because collagen and structure in younger skin can look very different from older skin. That's key for understanding healing, chronic wounds and how therapies may behave across ages and skin tones.</p>



<p>"We're using these advanced technologies to try to augment the body's ability to rebuild tissue structure," Dr. Feinberg says. He explains that collagen is the body's primary structural protein, so his lab focuses on bioprinting collagen in ways that mimic native tissue at microscopic scales. Using biologic materials rather than synthetic ones helps printed tissues behave more like the real thing and may improve how future implants integrate with the body.&amp;nbsp;</p>



<p>Dr. Wyles highlights the team's work toward diagnostic and preclinical testing uses, with an emphasis on building an alternative to animal models. Printed skin can be observed as a living system, measured through its structure and secreted signals, then challenged with topical therapies to see how it responds.</p>



<p>Dr. Feinberg adds that moving away from animal testing is a growing priority, and engineered human tissue models may improve prediction because animal physiology differs from humans. The shared challenge is validation: proving that the models are reproducible and reliably predictive.</p>



<p>The episode also digs into senescent "<a href="https://newsnetwork.mayoclinic.org/discussion/a-new-tool-to-find-hidden-zombie-cells/">zombie cells</a>," which stop dividing but do not die. Dr. Wyles explains they can accumulate with age and in chronic wounds, releasing signals that influence the surrounding tissue. Her team studies patient samples to map these cells in conditions such as diabetic foot ulcers, then uses those learnings to build more realistic printed models, including patient-specific versions.</p>



<p>Both guests discuss how bioprinted skin for routine clinical use will take time. Progress depends on carefully defining the most urgent clinical problems, proving performance and scaling manufacturing. Potential future applications discussed include improved wound patches for burns, chronic wounds and tissue-loss injuries, along with better ways to test treatments before they ever reach patients.</p>



<p>Listen to the latest episode of "<a href="https://careinfo.mayoclinic.org/tomorrows-cure-podcast?mc_id=global&amp;amp;utm_source=newsnetwork&amp;amp;utm_medium=l&amp;amp;utm_content=tcseasontwoepisodeeight&amp;amp;utm_campaign=mayoclinic&amp;amp;geo=global&amp;amp;placementsite=enterprise&amp;amp;invsrc=other&amp;amp;cauid=190207">Tomorrow's Cure</a>" wherever you get your podcasts. You can explore the full library of episodes and guests on the show's page.</p>



<p></p>



<p></p>



<p></p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/tomorrows-cure-3d-bioprinting-living-human-skin-to-improve-wound-care-testing/">Tomorrow&amp;#8217;s Cure: 3D bioprinting living human skin to improve wound care,&nbsp;testing&nbsp;</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Skinspan-Bioprinting_Episode-Art_3000x3000.jpg</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/TC_Skinspan-Bioprinting_YT-Thumbnail_1280x720.jpg</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Saranya Wyles]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Tomorrow's Cure]]></mayoclinic:mctag>	</item>
		<item>
		<title>New CT imaging oral contrast agent improves visualization of bowel anatomy, clinical trial data show</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/new-ct-imaging-oral-contrast-agent-improves-visualization-of-bowel-anatomy-clinical-trial-data-show/</link>
		
		<dc:creator><![CDATA[Ethan Grove]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 19:24:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Minnesota]]></category>
		<category><![CDATA[News Releases]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Joel Fletcher]]></category>
		<category><![CDATA[Minnesota News Releases]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=409666</guid>

					<description><![CDATA[<p>ROCHESTER, Minn. — In a new pilot feasibility study, researchers from Mayo Clinic, the University of Washington School of Medicine, the University of California San Francisco, and Nextrast Inc. found that a new imaging oral agent, also known as a "contrast agent," helps radiologists better see bowel structures and disease in CT imaging when compared [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/new-ct-imaging-oral-contrast-agent-improves-visualization-of-bowel-anatomy-clinical-trial-data-show/">New CT imaging oral contrast agent improves visualization of bowel anatomy, clinical trial data show</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/image-1024x683.png" alt="A technologist prepares a patient for a CT scan" class="wp-image-409648" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/image-1024x683.png 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/image-300x200.png 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/image-768x512.png 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/image-1536x1024.png 1536w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/image.png 1687w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">A technologist prepares a patient for a CT scan.</figcaption></figure>



<p>ROCHESTER, Minn. — In a new <a href="https://link.springer.com/article/10.1007/s00261-025-05308-w" target="_blank" rel="noreferrer noopener">pilot feasibility study</a>, researchers from <a href="https://www.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic</a>, the University of Washington School of Medicine, the University of California San Francisco, and Nextrast Inc. found that a new imaging oral agent, also known as a "contrast agent," helps radiologists better see bowel structures and disease in CT imaging when compared with the current oral contrast agents.</p>


<div class="wp-block-image">
<figure class="alignright size-medium"><img loading="lazy" decoding="async" width="300" height="200" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Fletcher_1577788_3776409_0013-300x200.jpg" alt="Portrait of Dr. Joel Fletcher" class="wp-image-409652" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Fletcher_1577788_3776409_0013-300x200.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Fletcher_1577788_3776409_0013-1024x682.jpg 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Fletcher_1577788_3776409_0013-768x512.jpg 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Fletcher_1577788_3776409_0013-1536x1024.jpg 1536w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/Fletcher_1577788_3776409_0013.jpg 1688w" sizes="auto, (max-width: 300px) 100vw, 300px" /><figcaption class="wp-element-caption">Joel Fletcher, M.D.</figcaption></figure>
</div>


<p>The introduction of a new oral contrast agent for CT imaging addresses common challenges in the diagnosis of bowel diseases, says by <a href="https://www.mayoclinic.org/biographies/fletcher-joel-g-m-d/bio-20053419" target="_blank" rel="noreferrer noopener">Joel Fletcher, M.D.</a>, lead author on the study and medical director of the <a href="https://www.mayo.edu/research/centers-programs/ct-clinical-innovation-center/overview" target="_blank" rel="noreferrer noopener">Mayo Clinic CT Clinical Innovation Center</a>. "The new oral contrast agent," he explains, "is ingested by patients prior to CT imaging and helps detect pathologies within and outside of the bowel wall in ways current imaging agents do not."</p>



<p>"We carefully designed this new class of oral contrast agent to overcome many of the diagnostic shortcomings of existing contrast agents for a broad range of diseases," says <a href="https://radiology.ucsf.edu/people/benjamin-yeh" target="_blank" rel="noreferrer noopener">Benjamin Yeh, M.D.</a>, a co-author on the study, radiologist at the University of California at San Francisco and co-founder of Nextrast, which created the new agent. "The Clinical Phase 2 results confirm that our dark agent can reveal previously impossible-to-detect findings, including very small bowel tumors and subtle inflammatory conditions that are often missed with conventional agents at CT."</p>



<p>In their <a href="https://link.springer.com/article/10.1007/s00261-025-05308-w" target="_blank" rel="noreferrer noopener">paper</a>, the authors report findings that suggest this new agent significantly improves visualization of inflammatory bowel disease (IBD) or cancer within the abdomen, and may provide earlier and more confident diagnoses.</p>



<p>The study compared CT scans of 32 patients with the dark borosilicate oral contrast agent and scans with conventional water or iodine-based oral contrast agents, to look at anatomical structures and disease presence.</p>



<p>"The novel dark borosilicate contrast agent has the potential to improve the assessment of numerous pathologies, including the detection of cancer and inflammatory disorders," says <a href="https://rad.uw.edu/people/amileto" target="_blank" rel="noreferrer noopener">Achille Mileto, M.D.</a>, a radiologist at the University of Washington School of Medicine and first author of the study.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/CT-Image-1024x576.jpg" alt="CT images from a patient who ingested the new oral solution that better distends the stomach (see the white S) and small bowel (asterisks) so that enhancing pathologies inside and outside the bowel wall can be better displayed and detected by radiologists." class="wp-image-409656" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/CT-Image-1024x576.jpg 1024w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/CT-Image-300x169.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/CT-Image-768x432.jpg 768w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/CT-Image.jpg 1360w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">CT images from a patient who ingested the new oral solution that better distends the stomach (see the white S) and small bowel (asterisks) so that enhancing pathologies inside and outside the bowel wall can be better displayed and detected by radiologists.</figcaption></figure>



<p>Evaluators identified clinically relevant findings in seven patients that were not detected using the standard contrast.</p>



<p>"CT scans performed with the new agent will likely do a better job of displaying pathologies in the stomach and proximal small bowel, areas where CT with traditional oral contrast performs poorly," Dr. Fletcher says. "Pathologies within the lumen will be better displayed because the lumen is more distended, and the brightness of the pathologies on the CT images will be increased, making them more conspicuous.”</p>



<p>The researchers say further study using a larger patient population is needed, but the initial findings show promise.</p>



<p>Review the <a href="https://link.springer.com/article/10.1007/s00261-025-05308-w" target="_blank" rel="noreferrer noopener">study</a> for a complete list of authors, disclosures and funding.</p>



<p>###</p>



<p><strong>About Mayo Clinic&amp;nbsp;<br></strong><a href="https://www.mayoclinic.org/about-mayo-clinic" target="_blank" rel="noreferrer noopener">Mayo Clinic</a>&amp;nbsp;is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the <a href="https://newsnetwork.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic News Network</a> for additional Mayo Clinic news.&amp;nbsp;</p>



<p><strong>Media contact:</strong></p>



<ul class="wp-block-list">
<li>Ethan Grove, Mayo Clinic Communications, <a href="mailto:newsbureau@mayo.edu" target="_blank" rel="noreferrer noopener">newsbureau@mayo.edu</a></li>
</ul>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/new-ct-imaging-oral-contrast-agent-improves-visualization-of-bowel-anatomy-clinical-trial-data-show/">New CT imaging oral contrast agent improves visualization of bowel anatomy, clinical trial data show</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/image_1x1.jpg</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/image_16x9.jpg</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Joel Fletcher]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Minnesota News Releases]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[News Releases]]></mayoclinic:mctag>	</item>
		<item>
		<title>Mayo Clinic researchers use AI to predict patient falls based on core density in middle age</title>
		<link>https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-use-ai-to-predict-patient-falls-based-on-core-density-in-middle-age/</link>
		
		<dc:creator><![CDATA[Vincent Jacobbi]]></dc:creator>
		<pubDate>Thu, 15 Jan 2026 14:00:00 +0000</pubDate>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[Minnesota]]></category>
		<category><![CDATA[News Releases]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[#Newsapp]]></category>
		<category><![CDATA[daily]]></category>
		<category><![CDATA[Dr. Jennifer St. Sauver]]></category>
		<category><![CDATA[Minnesota News Releases]]></category>
		<guid isPermaLink="false">https://newsnetwork.mayoclinic.org/?p=409582</guid>

					<description><![CDATA[<p>ROCHESTER, Minn. — Artificial intelligence (AI) applied to abdominal imaging can help predict adults at higher risk of falling as early as middle age, a new Mayo Clinic study shows. The research, published in Mayo Clinic Proceedings: Digital Health, highlights the importance of abdominal muscle quality, a component of core strength, as a key predictor [&amp;#8230;]</p>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-use-ai-to-predict-patient-falls-based-on-core-density-in-middle-age/">Mayo Clinic researchers use AI to predict patient falls based on core density in middle age</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="800" height="533" src="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/GettyImages-1390882860.jpg" alt="" class="wp-image-409584" srcset="https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/GettyImages-1390882860.jpg 800w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/GettyImages-1390882860-300x200.jpg 300w, https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/GettyImages-1390882860-768x512.jpg 768w" sizes="auto, (max-width: 800px) 100vw, 800px" /></figure>



<p>ROCHESTER, Minn. — Artificial intelligence (AI) applied to abdominal imaging can help predict adults at higher risk of falling as early as middle age, a new <a href="https://www.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic</a> study shows. The research, published in <a href="https://www.sciencedirect.com/science/article/pii/S2949761225001063" target="_blank" rel="noreferrer noopener">Mayo Clinic Proceedings: Digital Health</a>, highlights the importance of abdominal muscle quality, a component of core strength, as a key predictor of fall risk in adults aged 45 years and older.</p>



<p>Falls are a leading cause of injury, especially among older adults. Mayo Clinic researchers found that early markers of fall risk may be detectable in <a href="https://www.mayoclinic.org/tests-procedures/ct-scan/about/pac-20393675" target="_blank" rel="noreferrer noopener">CT scans</a> that many patients have for other reasons.</p>



<p>Working with radiology bioinformatics experts, they set out to determine whether AI-derived measurements of fat distribution, muscle size and density and bone quality could reveal early signs of noteworthy physical changes.</p>



<p>They found that muscle density, a measure of muscle quality, was a much stronger predictor of fall risk than muscle size.</p>



<p>"Muscle size is just a measure of how big your muscles are," says lead author <a href="https://www.mayo.edu/research/faculty/st-sauver-jennifer-ph-d/bio-00027743" target="_blank" rel="noreferrer noopener">Jennifer St. Sauver, Ph.D.</a>, an epidemiologist at <a href="https://www.mayoclinic.org/patient-visitor-guide/minnesota" target="_blank" rel="noreferrer noopener">Mayo Clinic in Rochester</a>. "Muscle density is different; on a CT scan, it's a measure of how 'dark' and homogenous the muscles are."</p>



<p>More homogenous muscles are denser and tend to have less fat in them, Dr. St. Sauver notes.</p>



<p>"Previous studies have suggested that muscle density, not size, is more strongly associated with physical strength and function," she says. "Our results support the idea that we should be focusing on muscle density, not muscle size, when we try to understand physical function."</p>



<p>The research team expected to see links between poorer performance on abdominal muscle measures and a higher incidence of falls in older adults, but what surprised them most was the strength of these associations in middle-aged adults and how strongly those measures predicted fall risk.</p>



<p>"Leg muscles have been associated with physical function, but our findings show that abdominal muscles also play a significant role," Dr. St. Sauver says.</p>



<p>The findings underscore the importance of maintaining good core strength throughout adulthood, she adds.</p>



<p>"One of the most important messages from this research is to keep your abdominal muscles in the best shape possible," Dr. St Sauver says. "Doing so may provide benefits that start in midlife and continue well into older adulthood."</p>



<p>For tips on improving your abdominal core strength, visit <a href="https://www.mayoclinic.org/healthy-lifestyle/fitness/in-depth/core-strength/art-20546851" target="_blank" rel="noreferrer noopener">mayoclinic.org</a>.</p>



<p>###&amp;nbsp;</p>



<p><strong>About Mayo Clinic</strong> <br><a href="https://www.mayoclinic.org/about-mayo-clinic" target="_blank" rel="noreferrer noopener">Mayo Clinic</a>&amp;nbsp;is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the <a href="https://newsnetwork.mayoclinic.org/" target="_blank" rel="noreferrer noopener">Mayo Clinic News Network</a> for additional Mayo Clinic news.</p>



<p><strong>Media contact:</strong></p>



<ul class="wp-block-list">
<li>Vincent Jacobbi, Mayo Clinic Communications, <a href="mailto:newsbureau@mayo.edu">newsbureau@mayo.edu</a></li>
</ul>
<p>The post <a href="https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-use-ai-to-predict-patient-falls-based-on-core-density-in-middle-age/">Mayo Clinic researchers use AI to predict patient falls based on core density in middle age</a> appeared first on <a href="https://newsnetwork.mayoclinic.org">Mayo Clinic News Network</a>.</p>
]]></content:encoded>
					
		
		
		<mayoclinic:mcimg1x1>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/A-woman-practices-yoga-on-a-mat-outdoors-in-a-park_GettyImages-1390882860_1x1.jpg</mayoclinic:mcimg1x1>
<mayoclinic:mcimg16x9>https://newsnetwork.mayoclinic.org/n7-mcnn/7bcc9724adf7b803/uploads/2026/01/A-woman-practices-yoga-on-a-mat-outdoors-in-a-park_GettyImages-1390882860_16x9.jpg</mayoclinic:mcimg16x9>
<mayoclinic:mctag><![CDATA[#Newsapp]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[daily]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Dr. Jennifer St. Sauver]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[Minnesota News Releases]]></mayoclinic:mctag><mayoclinic:mctag><![CDATA[News Releases]]></mayoclinic:mctag>	</item>
	</channel>
</rss> 